CAMBRIDGE & LEXINGTON, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.

Shares of Frequency Therapeutics FREQ surged 77.48% on Friday, after management announced that the company entered into a definitive agreement with RNA editing company, Korro Bio, to merge in an ...

Merger aims to advance RNA editing programs. Korro Bio, a ribonucleic (RNA) editing organization, and Frequency Therapeutics Inc., have announced plans to merge into one company as part of an ...

(RTTNews) - Korro Bio, Inc., an RNA editing firm, and Frequency Therapeutics, Inc. (FREQ), announced on Friday that they have signed a deal to combine the two firms in an all-stock transaction. The ...

Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial Shares to trade on Nasdaq under ...

A pending reverse merger with troubled Frequency Therapeutics is giving new meaning to Korro Bio’s slogan, “Edit the message. Rewrite the future.” For Korro, a developer of RNA-edited therapies, the ...

Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with ...

CAMBRIDGE & LEXINGTON, Mass., July 14, 2023--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics, Inc.